Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Nutt

Showing results (41-50 of 388) with videos related to

Pageof 39
Sort By:
Journal of Psychopharmacology (Oxford, England)|July 5, 2021
More than just smoke: Psychopharmacology of cannabinoidsAllan H Young, David J Nutt
Pharmacology Research & Perspectives|August 7, 2019
Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successesAnn G Hayes, David J Nutt
The Journal of Clinical Psychiatry|January 20, 2004
Structural and functional brain changes in posttraumatic stress disorderDavid J Nutt, Andrea L Malizia
Journal of Psychopharmacology (Oxford, England)|August 2, 2013
Anhedonia revisited: is there a role for dopamine-targeting drugs for depression?Spilios V Argyropoulos, David J Nutt
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 22, 2014
Where now for schizophrenia research?David J Nutt, Anna C Need
Journal of Psychopharmacology (Oxford, England)|July 29, 2010
What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacologyDavid J Nutt, Celia L Feetam
Journal of Psychopharmacology (Oxford, England)|March 29, 2014
Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs)A Richard Green, David J Nutt
Handbook of Clinical Neurology|May 22, 2012
AnxiolyticsLindsey I Sinclair, David J Nutt
Lancet (London, England)|May 20, 2014
Legal highs: a problem of definitions? - Authors' replyLeslie A King, David J Nutt
CNS Spectrums|September 30, 2006
Understanding the neurobiology of comorbidity in anxiety disordersDavid J Nutt, Dan J Stein
Pageof 39

Showing results (41-50 of 388) with videos related to

Sort By:
Pageof 39
Journal of Psychopharmacology (Oxford, England)|July 5, 2021
More than just smoke: Psychopharmacology of cannabinoidsAllan H Young, David J Nutt
Pharmacology Research & Perspectives|August 7, 2019
Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successesAnn G Hayes, David J Nutt
The Journal of Clinical Psychiatry|January 20, 2004
Structural and functional brain changes in posttraumatic stress disorderDavid J Nutt, Andrea L Malizia
Journal of Psychopharmacology (Oxford, England)|August 2, 2013
Anhedonia revisited: is there a role for dopamine-targeting drugs for depression?Spilios V Argyropoulos, David J Nutt
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 22, 2014
Where now for schizophrenia research?David J Nutt, Anna C Need
Journal of Psychopharmacology (Oxford, England)|July 29, 2010
What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacologyDavid J Nutt, Celia L Feetam
Journal of Psychopharmacology (Oxford, England)|March 29, 2014
Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs)A Richard Green, David J Nutt
Handbook of Clinical Neurology|May 22, 2012
AnxiolyticsLindsey I Sinclair, David J Nutt
Lancet (London, England)|May 20, 2014
Legal highs: a problem of definitions? - Authors' replyLeslie A King, David J Nutt
CNS Spectrums|September 30, 2006
Understanding the neurobiology of comorbidity in anxiety disordersDavid J Nutt, Dan J Stein
Pageof 39